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Asthma is a chronic inflammatory disease that has reached epidemic proportions worldwide. It is treatable
in the majority of patients, but there is no cure. Moreover, a proportion of patients suffer from severe, difficult-
to-control disease with daily symptoms and high morbidity, making it imperative that we continue to improve
our understanding of the underlying mechanisms of this disease. Severe asthma is a heterogeneous condition.
A systematic approach to identify specific asthma phenotypes, including clinical characteristics and inflam-
matory processes, is the first step toward individualized, logical therapy. This review focuses on the need to
characterize severe asthma phenotypes and on novel, targeted molecular treatment options currently under
development.
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sthma is associated with significant morbidity
and mortality and is one of the most common
long-term conditions worldwide (1). The preva-
lence of asthma has been rising over the past decade and
currently affects up to 10% of the population in devel-
oped countries (2, 3). Fortunately, a majority of patients
achieve control if they take their medication regularly
and as prescribed, and international guidelines assist the
treating physician to implement a stepwise escalation of
treatment until symptoms are controlled (2). However, a
substantial number of patients fail to gain clinical benefit
from any of the standard treatments. Poor compliance
may be a reason for this. However, it is noteworthy that
studies assessing asthma control observed persistent
symptoms in over 20% of patients despite treatment ad-
herence in exceptional trial circumstances and in selected
patient groups (3). It is therefore widely acknowledged
that a small proportion of patients have a genuine poor
response, in particular to corticosteroids. These patients
have a greater risk of dying of their disease and their lives
are often blighted by their condition, notwithstanding the
disproportional amount of healthcare resources spent.
A well-defined, unbiased approach that defines the
clinical characteristics that specify distinct phenotypes
of asthma is critical for a better understanding of disease
pathogenesis and thus successful management.
It is essential to differentiate severe asthma from
difficult-to-control asthma. Assessment of each and every
patient presenting with recurrent episodes of wheezing,
chest tightness, and/or cough requires a careful history
focusing on symptoms, exacerbating triggers and occupa-
tional as well as environmental factors. With the correct
diagnosis established, systematic evaluation has the po-
tential to identify up to half of previously deemed severe
asthmatics as difficult-to-treat asthmatics (4, 5). Patients
can be labeled as suffering from severe asthma with
ongoing symptoms after an alternative diagnosis has
been excluded, comorbidities have been treated, allergen
exposures are being avoided and, last but not least, adher-
ence with treatment and inhaler technique has been
checked (Fig. 1).
In 2013, the international European Respiratory
SocietyAmerican Thoracic Society guidelines classified
severe asthma as a disease that requires treatment with
high-dose inhaled corticosteroids and/or systemic corti-
costeroids to prevent it from becoming uncontrolled or
that remains uncontrolled despite this therapy (6). Any
of the following criteria qualifies a patient as having
ongoing symptoms and therefore severe asthma:
1) Consistently poor symptom control: Asthma Con-
trol Questionnaire (ACQ) score is consistently 1.5
or Asthma Control Test (ACT) score is B20.
2) Frequent severe exacerbations requiring at least
courses of oral corticosteroids for a minimum of
3 days in the previous year.
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3) One or more hospitalization, intensive care unit ad-
mission, or invasive ventilation in the previous year.
4) Forced expiratory volume (FEV1)B80% predicted
(with FEV1/FVC (forced vital capacity) reduced to
less than the lower limit of normal).
Comorbidities
Atopic rhinosinusitis, gastroesophageal reflux disease
(GERD), sleep apnea, and obesity are well-known
comorbidities that can aggravate and perpetuate and/or
masquerade as asthma. Epidemiological studies report
less atopy by skin test in severe asthma, but a high
prevalence of chronic rhinosinusitis and nasal polyposis
(7, 8). Severe asthma is disproportionally high in aspirin-
exacerbated respiratory disease (AERD), where the
majority of patients suffer from nasal polyposis (9).
Symptoms of GERD include cough and chest tightness.
Heartburn and indigestion contribute to night awakenings
and may mimic asthma. Prevalence of GERD in asthma
is variable and can range from 12 to 85% (10). Treatment
has proven beneficial for asthma-related quality of life. It
was shown to reduce nocturnal symptoms and exacerba-
tion frequency, and some studies report reduction in the
use of short-acting beta2 agonists (11). Notwithstanding
this, bronchodilators can potentially aggravate GERD by
reducing esophageal sphincter tone (12).
Obesity is a major risk factor for asthma, and the
epidemic increase in obesity is likely to be a significant
contributor to the increase in numbers of patients with
severe asthma. Factors such as insulin resistance, altered
adaptive and innate immunity, changes in mechanical
loading of the chest wall and abdomen, and increased
airway hyperresponsiveness secondary to low-lung-volume
breathing have all been linked to obesity-related asthma
(13). Weight loss has been shown to improve asthma
control, and a recent paper reported reversal of a pro-
inflammatory cytokine milieu after bariatric surgery
(14, 15). Treatment of obesity-related asthma with corti-
costeroids often proves disappointing. The pivotal role of
adipose tissue resident immune cells (i.e. macrophages and
mast cells as well as proinflammatory adipocytokines)
makes them targets for novel biological treatments such
as peroxisome proliferator activated receptor (PPAR)
agonists and, in particular, in association with sputum
eosinophilia, anti-interleukin (IL)-5 (16, 17).
Severe asthma is frequently associated with fungal and/
or mold sensitivity. Patients with persistently uncontrolled
asthma are often chronically colonized with Aspergillus,
Candida, Penicillium, and Curvularia species (1820). All
patients should undergo both skin prick testing (SPT) and
specific serum IgE tests: SPT has a sensitivity of around
5060%, less than half of patients have a positive reaction
to both tests and there is generally insufficient concor-
dance between the two tests (2123).
The first case reports linking asthma and obstructive
sleep apnea (OSA) emerged in the late 1970s (24). Snoring,
observed apnea, and poorly controlled asthma are closely
linked, and patients who have OSA and nocturnal asthma
may have similar clinical presentations (2528). Treatment
with continuous positive airway pressure (CPAP) signifi-
cantly improves asthma quality of life, lung function, and
short-term beta2 agonist requirements (29, 30).
Anxiety and depression are subjective emotions that
may escape the attention of clinicians and patients with
chronic diseases. Patients with severe asthma are under
protracted distress and are at increased risk of developing
psychiatric disorders, most commonly panic disorder,
depression, and anxiety (31, 32). Moreover, studies have
shown decreased asthma control with higher exacer-
bation rates in patients suffering from anxiety with or
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Fig. 1. Investigation and treatment of severe asthma.
A stepwise approach toward individualized asthma treatment incorporates a systematic assessment with a critical review of
diagnosis, comorbidities and compliance.
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without depression (33, 34). The challenges of under-
standing and responding appropriately to the emotional
factors of the chronic disease that asthma is mustn’t
be neglected, and patients might benefit from formal
psychological support services.
Smoking is as common in asthmatics as it is in the
general population (35, 36). Smoking asthmatics have a
more rapid decline in lung function, more symptoms and
exacerbations than nonsmokers and an impaired steroid
response (37). Their inflammatory profile in blood and
sputum differs compared to that of nonsmoking asth-
matics (38). All patients should be offered smoking ces-
sation advice (3840).
Asthma phenotyping
Recently, a significant effort has been directed at defining
severe asthma and in particular its subgroups or pheno-
types. Asthma is a heterogeneous disease, and phenotype-
specific therapies promise enhanced treatment success.
A phenotype is defined as the apparent characteristics
of an organism resulting from its interactions with the
environment and its genetic makeup (41).
Historically, asthma has been termed a T-helper cell
type 2 (Th2)-driven disease characterized by reversible
airway obstruction, thickened airway smooth muscle
cells, subepithelial fibrosis, and a characteristic aberrant
immune regulation with a predominance of Th2 cells
secreting cytokines IL-4, IL-5, and IL-13 (42). IL-4 is a
key element in driving differentiation from naı¨ve Th0 cells
to Th2 cells, and it promotes B cell class switching to IgE
production, mast cell growth, and eosinophil recruitment
(43). IL-5 is responsible for driving eosinophil differe-
ntiation, survival and tissue cytotoxicity (44), and IL-13
mediates airway hyperactivity and increased mucus pro-
duction and also promotes B cell IgE production. Other
cells known to be central to allergic inflammation are
mast cells, eosinophils, neutrophils, macrophages, dendri-
tic cells and, in recent years, invariant natural killer T cells,
innate lymphoid cells, and Th17 cells (Fig. 2).
Several approaches have been taken to characterize
asthma subgroups. The Severe Asthma Research Program
(SARP) identified five asthma subphenotypes by unbiased
cluster analysis, three of which are severe asthma (45): the
early-onset allergic type and the late-onset eosinophilic
phenotype are both orchestrated by Th2 cells. They are
clinically distinct yet overlap immunologically. A Th2-
cell signature is further believed to play a predominant
role in exercise-induced asthma (EIA), with mast cells and
their mediators understood to be driving inflammation
in EIA (46) and AERD. A lack of Th2 biomarkers is




























Fig. 2. Immunopathology in asthma.
Allergens are presented to naı¨ve T-helper cells (Th0) via antigen presenting cells (APCs), resulting in the differentiation into
Th1, Th17 and Th2 cells and the release of cell-specific cytokines. Th2 cytokines mediate airway eosinophil and mast cell
recruitment, B-cell IgE isotype class switching, and mucus secretion. Allergen specific B-cells switch from IgM-producing to
IgE-producing cells. Interleukin-17, which is produced by Th17 cells, mediates airway neutrophilia by inducing the produc-
tion of CXC chemokine. ILinterleukin, TCRT-cell receptor, IFN-ginterferon gamma, TNFtumor necrosis factor,
FcoRhigh-affinity IgE receptor.
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In another study using cluster analysis, sputum eosi-
nophilia was incorporated. Consequent upon this, a
phenotype of early-onset severe atopic asthma, late-onset
asthma with persistent eosinophilia, and a cluster of
obese females with late-onset asthma without eosinophi-
lia were identified (47).
Molecular phenotyping has led to the development
of biomarkers that specifically target Th2 responses in
the lung: Woodruff and colleagues identified periostin
(POSTN), chloride channel regulator 1 (CLCA1), and
serpin peptidase inhibitor, clade B, member 2 (SERPINB2)
as epithelial genes that were specifically induced in asthma
and directly regulated by IL-13 in vitro (48). They further
identified patients with distinctly higher levels of IL-5 and
IL-13, termed Th2-high asthma. This was in contrast with
patients with cytokine expression similar to that of healthy
controls, including Th1 cytokines IL-12 and interferon
gamma (IFNg), which were significantly lower in the
Th2-high group. The Th2-high and Th2-low groups also
differed clinically, with the Th2-high group showing sig-
nificant higher atopy and higher eosinophil levels in
peripheral blood and bronchoalveolar lavage (BAL).
Of particular interest was their observation of corticoste-
roid responsiveness: lung function of Th2-low asthmatics
failed to improve following treatment with inhaled corti-
costeroids; in fact, patients’ FEV1 deteriorated in the first
month, suggesting a detrimental effect of corticosteroids
in Th2-low asthma (48).
Novel therapies  targeting the right patient:
Th2-high asthma
Omalizumab remains so far the most successfully applied
monoclonal antibody to treat allergic Th2-high asthma
by reducing the exacerbation rate. Omalizumab is a
humanized IgG1k monoclonal antibody that specifically
binds to free human immunoglobulin E (IgE), but not
to IgE that is already bound by the high-affinity IgE
receptor (FcoRI) on the surface of mast cells, basophils,
and antigen-presenting dendritic cells. Steric hindrance
by the receptor means the receptor is not accessible to
omalizumab binding, thus averting anaphylaxis. In a
number of studies conducted so far, patients treated with
omalizumab reported significant improvements in asthma-
related symptoms, allowing for a reduction in corticoster-
oid and rescue inhaler use (4951). It appears that patients
with blood eosinophilia, high levels of exhaled nitric oxide,
and serum periostin most benefit from anti-IgE treatment
(52). However, evidence is now emerging that omalizumab
has a role in non-atopic asthma. A recent trial demon-
strated significantly increased asthma control in 29 non-
atopic patients and a trend to reduced exacerbation rates
and improved lung function (53, 54). A small randomized
controlled trial comparing treatment with omalizumab
and placebo in non-atopic asthmatics over a period of 16
weeks found a trend toward a decrease in exacerbations
and a significant improvement in lung function in omali-
zumab-treated patients, as compared with the placebo
group. In addition, the authors showed that the expression
of the high-affinity IgE receptor on blood plasmacytoid
dendritic cells decreased significantly in the active group
but not in the placebo group (54). Larger trials, and in
particular trials shedding light on how best to identify
non-atopic patients who are likely going to respond to
anti-IgE treatment, are needed.
The success of anti-IgE therapy is limited by the fact
that IgE production is not affected. Treatment has to
be given regularly and on a long-term basis. Brightbill
et al. have successfully created a monoclonal antibody
against theM1? segment of membrane IgE on human IgE-
switched B cells, resulting in depletion of IgE-switched
B cells via apoptosis or/and antibody-dependent cell-
mediated cytotoxicity (55). Total IgE levels were reduced
without other immunoglobulin isotypes being affected.
A phase IIb randomized controlled trial is currently
testing its efficacy in uncontrolled allergic asthma, and
study results are expected in 2015 (http://clinicaltrial.gov/
ct2/show/NCT01582503).
Promising newer treatments targeting the Th2 pathway
with steroid-sparing potential include the anti-IL-5 anti-
body mepolizumab. The first randomized controlled trials
with anti-IL-5 were conducted in patients with mild to
Table 1. Asthma phenotypes according to their cytokine profiles divided into Th2-high and Th2-low asthma (41)
T cell
signature Phenotype Biomarkers Therapy
Th2-high Early-onset allergic Specific IgE, SPT Corticosteroids, anti-IgE
Late-onset
eosinophilic
Sputum eosinophilia, IL-5 Poor response to corticosteroids, anti-IL-5
Exercise induced Mast cells Leukotriene receptor antagonists, SABA
Th2-low Obesity related Mast cells, adiponectin, Th1
cytokines
Poor response to corticosteroids
Weight loss, PPAR agonists
Neutrophilic Th17, sputum neutrophilia Vitamin D, p38 MAPK inhibitors, Macrolides. Poor response to
corticosteroids
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moderate asthma (56, 57). These studies failed to show
a beneficial effect on lung function. However, after tar-
geting patients with severe asthma and refractory airway
eosinophilia and choosing the correct primary out-
come (i.e. asthma exacerbations), anti-IL-5 treatment has
been shown to significantly reduce exacerbations and oral
corticosteroid doses required to control symptoms, and it
has been well tolerated during the study period of over a
year (58). Benralizumab, an IL-5 receptor alpha subunit
(IL-5Ra) antibody, not only reduced peripheral blood
eosinophils but significantly reduced eosinophil counts in
airway mucosa and submucosa (59). However, neither of
the two treatments has had any effect on lung function or
patient-rated asthma control.
Clinical trials have also investigated targeted therapies
against the Th2 cytokines IL-4 and IL-13. Pitrakinra is
an IL-4 mutein, which binds to the IL-4Ra subunit and
prevents the inflammation induced by IL-4 and IL-13.
It has been shown to reduce allergen-induced airway res-
ponses when given in inhaled or subcutaneous form in
a study of mild asthmatics and to reduce exacerbation
rates in those with eosinophilia (60, 61). In moderate to
severe asthma, the fully human monoclonal IL-4R-a
dupilumab improved lung function, symptoms and ex-
acerbation rate (62).
Periostin has proven to be a prognostic biomarker for
treatment with the anti-IL-13 antibody Lebrikizumab.
A recent study demonstrated that treatment with Lebri-
kizumab increased FEV1 in patients with a high serum
periostin level (63). To date, the most successful anti-Th2
cytokine therapies have focused on accurate identification
of a patient’s phenotype to allow for personalized treat-
ment regimes.
Non-Th2-high asthma: a different challenge
Treatments targeting other possible inflammatory media-
tors have shown less clear evidence of clinical benefit,
and the reason for this might stem from the difficulty of
a clear definition: Th2-low asthma remains identified by
the absence of Th2 biomarkers. Although the presence of
a neutrophilic phenotype of asthma has been suggested,
its use as a biomarker is imperfect. In contrast to the
significant association between blood eosinophilia and
airway eosinophilia in patients with asthma (who are not
treated with systemic corticosteroids), there is no correla-
tion at all between blood neutrophilia and airway neu-
trophilia (64). Furthermore, there is no consent as to
the level of airway neutrophilia that would define pathol-
ogy; neutrophils, unlike eosinophils, are a normal com-
ponent of the cells retrieved in induced sputum. There
are robust data, however, that the later onset, obese, non-
eosinophilic phenotype is often particularly steroid in-
sensitive and difficult to control. Interestingly, patients
with severe asthma are found to have higher levels of
the pro-inflammatory cytokine IL-17A in sputum and
BAL, and the severity of airway hypersensitivity correlates
with airway neutrophilia and levels of IL-17A expression
(6567). Studies in mice and humans suggest an associa-
tion between steroid resistance and Th17-mediated dis-
ease: adoptive transfer of Th17 cells resulted in increased
levels of CXC chemokines and G-CSF in the BAL
fluid of SCID mice, and treatment with dexamethasone
resulted in increased neutrophil numbers but no improve-
ment of airway hyperresponsiveness (68). Glucocorticoid
resistance is associated with an increased expression of
the transcriptionally inactive glucocorticoid receptor beta
(GR-b) (6971). Furthermore, GR-b increases in response
to exogenous IL-17A and IL-17F, an effect that was more
prominent in asthmatics than in healthy controls (72).
Further accounting for corticosteroid insensitivity are
defects in glucocorticoid receptor binding and activation
of transcription factors such as AP1, which is activated by
pro-inflammatory cytokines such as tumor necrosis factor
alpha (TNFa) or through failure to induce regulatory
cytokines like IL-10 (73).
Anti-TNFa treatment was tested in severe (etanercept)
(74, 75) and moderate (infliximab) (76) asthmatics and
resulted in improved asthma control, FEV1, and bron-
chial hyperreactivity. However, the effect ceased as soon
as the drug was discontinued. The fully human anti-TNF
antibody golimumab did not have any clinical benefit,
but resulted in an increase of respiratory infections and
malignancies leading to an early discontinuation of the
trial (77).
In a randomized controlled trial, the human anti-IL-17
receptor monoclonal antibody brodalumab was not supe-
rior to placebo in terms of asthma control (78). Interest-
ingly, the authors observed a nominal significance in a
subgroup of patients with high bronchodilator reversibil-
ity. Further studies of brodalumab in this asthma sub-
population are warranted. Anti-IL-9 (79), agents targeting
TSLP (80), chemokine inhibitors (CCR3 and CCR4) (81),
phosphodiesterase and kinase inhibitors (82) and the use
of vaccination (83) with the aim to shift from Th2 to Th1
are all under development, but have yet to show any clear
clinical benefit.
Deficiency in serum vitamin D has been linked to
predisposing individuals to chronic inflammatory lung
disease, such as asthma and viral respiratory infections,
with higher rates of hospital admission for respiratory
diseases (8486). Reports have shown a positive correla-
tion between vitamin D deficiency and asthma prevalence
(8789). Manipulation of vitamin D status for therapeutic
benefit in asthma is currently highly topical, with studies
suggestive of a role in steroid-refractory asthma (90, 91).
Macrolide antibiotics have anti-inflammatory and
immune-modulatory effects. They also increase gastro-
intestinal motility and to that extent might prove bene-
ficial in patients with significant GERD. They have been
proven effective in chronic respiratory diseases such as
Severe asthma
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cystic fibrosis (CF) and chronic obstructive pulmonary
disease (COPD). They have been shown to reduce severe
exacerbations in patients with non-eosinophilic asthma
and to have significantly improved the Asthma Quality of
Life Questionnaire score (92). However, chronic antimi-
crobial use is associated with the risks of population
resistance, and treatment should be restricted to severe
asthma patients at greatest unmet need despite optimal
asthma management.
Methotrexate has proven a valid agent in patients who,
despite long-term treatment with oral glucocorticoster-
oids, fail to gain satisfactory control of their asthma
(93). Due to considerable side effects, close monitoring is
needed and treatment should only be initiated in specia-
list centers.
Bronchial thermoplasty
Smooth muscle hyperplasia is a distinctive feature of
asthma. Applying radiofrequency energy to subsegmental
airways has been shown to reduce muscle mass at the site
of thermoplasty. Trials demonstrated a reduction in the
number of severe asthma exacerbations and an improve-
ment in asthma-specific quality of life (94), and a recent
study found no adverse events after a 5-year follow-up
period (95). Although guidelines recommend bronchial
thermoplasty for adults with severe asthma that is not
controlled with inhaled corticosteroids and long-acting
beta2 agonists (LABAs), it is currently unclear which
phenotypes respond best to the treatment. Studies are
needed to identify the phenotype of patients who will
derive significant clinical benefit most from this invasive
procedure.
Conclusion
Asthma is common, and in most cases it is a treatable
disease. However, patients with difficult-to-treat asthma
remain a challenge for every healthcare professional, and
there is a significant unmet clinical need. It has become
abundantly clear that asthma is a heterogeneous dis-
ease in its course and variation in response to treatment.
A systematic approach to the complexity and diversity
of asthma pathophysiology is essential. Up until recently,
trials testing anti-inflammatory therapy based on target-
ing cytokines have, despite highly promising results in
animal models, proven to be disappointing. However,
in carefully selected patients, when asthma phenotypes
are taken into account, novel biological treatments may
lead to significant advances. Discriminatory biomarkers
and genetic profiling may aid identification in support
of personalized pharmacotherapy. Within the next 5 to
10 years, logical, targeted therapies will be available for
patients with Th2-high severe asthma, and our under-
standing of the mechanisms driving Th2-low asthma will
be significantly advanced.
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